<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054166</url>
  </required_header>
  <id_info>
    <org_study_id>EVE-CWM-01</org_study_id>
    <nct_id>NCT05054166</nct_id>
  </id_info>
  <brief_title>Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study</brief_title>
  <official_title>Efficacy of Everolimus-containing Chemotherapy in HER2 Negative Metastatic Breast Cancer Patients With PI3K/AKT/mTOR Mutations: A Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <brief_summary>
    <textblock>
      The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in&#xD;
      metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic&#xD;
      breast cancer patients with PI3K/AKT/mTOR mutations treated with everolimus-containing&#xD;
      chemotherapy were retrospectively analyzed.The genetic profile in PI3K/AKT/mTOR pathway was&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PI3K/AKT/mTOR pathway is frequently altered in breast cancer. Everolimus is a selective&#xD;
      inhibitor of mammalian target of Rapamycin (mTOR).The benefit of everolimus in metastatic&#xD;
      breast cancer patients with PI3K/AKT/mTOR mutations remains unclear, especially in TNBC&#xD;
      patients. The study aimed to investigate the efficacy of the everolimus-containing&#xD;
      chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.&#xD;
&#xD;
      14 cases of HER2- metastatic breast cancer participants with PI3K/AKT/mTOR mutations treated&#xD;
      with everolimus-containing chemotherapy were retrospectively analyzed.The genetic profile in&#xD;
      PI3K/AKT/mTOR pathway was studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>The PFS was defined as the interval from the date of taking the everolimus-containing chemotherapy to the date of the first occurrence of disease progression or death from any cause,whichever came first, assessed up to 24 months.</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <condition>PI3K/AKT/mTOR Pathway Mutation</condition>
  <condition>Everolimus</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, it was a retrospective study.</intervention_name>
    <description>This study aimed to retrospectively investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.There was no intervention.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HER2- metastatic breast cancer patients with PI3K/AKT/mTOR mutations treated with&#xD;
        everolimus-containing chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with HER2- metastatic breast cancer&#xD;
&#xD;
          2. Patients with PI3K/AKT/mTOR mutation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients treated with endocrinotherapy and everolimus.&#xD;
&#xD;
          2. The efficacy evaluation could not be available.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>29 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-jia Wang, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Wen-Ming Cao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

